Must have taken some patience to hold that during the past few months where it was consolidating ! Bugger on missing out on that but hey theres always oppurtunites though :)
Printable View
Brilliant, Sparky!! Love both the music and PEB. Enjoy your comments.
Garfy.
In at average 2.55, out at 5.50, I can't complain. Still holding some but not as many as I would like :-(
Sparky's right about this one, the success of PEB is just around the corner I think too. When they start selling to the US/Europe is when we will see some more amazing gains. To top that off, I think they will be sustainable gains backed up by actual profits and dividend payments (I am picking first dividend in the first half of next year!).
I don't work like that. The money I am investing in shares is money that I can afford to lose (relatively speaking) and invest long term for the divies. Therefore my sell price/profit price is based on (in the order I think about them):
1. When the companies fundamentals change or its potential is exhausted.
2. When there are other better oppourtunities on the market.
3. I need the money (in the case of Diligent I could have used money from other investments but the break cost was too high, I planned a little poorly).
4. When my wife needs the money :-)
For PEB, the price I might start selling is above $6, if the company continues to go from strength to strength and the above factors don't come into play. At that stage they will have a good dividend stream though so even then I will only sell if I want to do something silly like buy a house.
Oh yeah - I probably aren't a big investor (holding 40k PEB with it being my second largest holding), so for me the reward/risks aren't massive. For others holding more it probably will be!
I'm with Blobbles for what its worth (and have said as much in previous posts). At my stage of life, I need to take aggressive positions to help fund the "after work" period. Have a large s/h at an average price of about 24c and if it goes, it goes. But I am confident it will grow rather well. Why not ride it ...they are a great company with a great outlook IMHO.
From http://www.finnewsnetwork.com.au/Com...d,-RM-Research
Quote:
According to most recent update from PEB’s management the company is on track to get CLIA certification by the end of March with commercial launch to follow shortly after.
Quote:
The US is the largest market opportunity for the Cxbladder and PEB is building a laboratory for the provision of the Cxbladder test to urologists and physicians across the US. The laboratory will be regulated under the Clinical Laboratories Improvement Amendment Act (CLIA) which will enable PEB to offer Cxbladder as a Laboratory Developed Test meaning it would not require FDA approval.Pacific Edge estimates that the annual potential US market for bladder cancer tests is approximately 1.8M tests. PEB uses the following assumptions to estimate the market:
- In the United States 1,000,000 patients per year present to their GP with haematuria;
- 68,800 patients are diagnosed each year with bladder cancer1;
- NCCN Clinical Practice Guidelines in Oncology specify that patients receive 12 monitoring cystoscopies in the five year monitoring period – 4 in the year of diagnosis and 2 in each following year.
All in all, PEB estimates 1,825,000 assays to be required per year. PEB’s new facility in Hershey, Pennsylvania would have a capacity of producing 260K tests per annum. These represents 14% of the overall market.
PEB expects smooth reimbursement process in US. A third party market survey of Medical and Benefits Review Committees for Health Insurers in the US that covered a wide spectrum of private plans showed a very high level of acceptance and concordance with the payers systems.
According to PEB, total supported price for Cxbladder using composite CPT coding for CMS patients is expected to be approximately US$786 per test. Reimbursement by insurers in the US generally occurs at 70% to 80% of the composite CPT code, meaning it will be in the range of US$550 - US$630 per test.
I see that Milford has released $4m from selling down some of their Diligent shares.
This has been the stock which gave Milford its exceptional fund gains in the last 2 years.
Other stocks like Ecoya and Moa had their moments for Milford but have not gone anywhere.
So they will be looking for the next supernova performer. And I suspect they will be thinking hard about PEB that is already rock and rolling ahead.
Try buying $4m worth.
They are going to find it very very hard.
I'd be feeling a little nervous myself if I was a holder....time to bank those gains I wud have thought! Although I was one of the first to pik PEB in the comp. I never expected such a stellar run like we've seen. Personally I think it's got ahead of itself once again and I wudnt be at all surprised to see a retraction in the SP very soon....BUT THEN WHAT WUD I KNOW?
Never wrong to take a profit - especially when it's 50% to 100% in a short time.
Just don't look back because I know of one investor who bought 100,000 Diligent shares at 38 cents and sold out at 60 cents. Never got back and laments every so often about the $500,000 odd he left at the table.
Then, there's another one who bought 50,000 at $1 and sold out at $4.00. Put it into PEB at 42 cents.
............and havnt we all done that ah Balance...........just one of the dangers of being a trader. Hard NOT to take the profit at times....and yes even harder to get back in IF they continue higher.............IF ONLY WE ALL HAD CRYSTAL BALLS. ( steel ones wud be kinda handy at times too)
What are peoples thoughts of CertNDx and the potential impact on Cxbladder?
http://www.predictivebiosci.com/for-...ls/CertNDX.cfm
sounds very much like the same technology to me........peb may have been beaten to the gun...?? I guess it was inevitable that there would be competition along the way.....they were never going to have it all to themselves as some might have been hoping/thinking!!
"The test is now being used and evaluated by clinicians in New Zealand and Australia to provide a clinical perspective in up to seven different ways with some clinicians using the test to aid their specific practice in more than one application."
They are also working on two other bladder cancer tests, one being a prognostic test, so the technology appears to have multiple applications which will hopefully keep them ahead of the inevitable competition.